Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.

As stricter fuel regulations and pressures intensify for a solution to the rising greenhouse gas emissions, the maritime ...

MASH Makes says the upgraded fuel addresses long-standing reliability and blending issues that have limited the use of CNSL ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today ...